- Construction of a multipurpose state-of-the-art Antibody-Drug Conjugate (ADC) manufacturing and aseptic fill/finish facility in Grangemouth, Scotland and enhancement of existing Active Pharmaceutical Ingredient (API) manufacturing in Morpeth, England
- Expansion is driven by several pipeline products moving to commercial scale, coupled with increased customer demand for ADCs and APIs
- The two expansions represent a total investment of £55 million; each will generate local employment opportunities for skilled workers
MUMBAI, India, Feb. 8, 2022 /PRNewswire/ -- Piramal Pharma Limited's Pharma Solutions business, a leading Contract Development and Manufacturing Organization (CDMO), today announced the expansion of its Antibody-Drug Conjugate (ADC) capabilities at the Grangemouth facility in Scotland and the investment in new Active Pharmaceutical Ingredient (API) infrastructure at the Morpeth facility in England. Together, these expansions and upgrades represent a total investment of approximately £55 million in the company's UK-based drug development and manufacturing capabilities as well as new employment opportunities for technical and operational staff.
Peter DeYoung, Chief Executive Officer, Piramal Pharma Solutions
Adrian Gillespie, Chief Executive of Scottish Enterprise
Ivan McKee, Minister for Business, Trade, Tourism and Enterprise, Scottish Government
Ceremonial Groundbreaking, Piramal Pharma Solutions Grangemouth Site Expansion. Left to right: Mr. Ivan McKee, Minister for Business, Trade, Tourism and Enterprise, Scottish Government and Mr. Peter DeYoung, Chief Executive Officer, Piramal Pharma Solutions
Artist’s Rendering of the Piramal Pharma Solutions Grangemouth Site Expansion
Grangemouth Site ADC Expansion
In the first phase of the Grangemouth site expansion, two new ADC manufacturing suites, operational by Q3 2023, will be added to the existing three. The building has been designed to accommodate further expansion, with planned future phases that include a new sterile fill/finish suite dedicated to ADCs and two additional large-scale manufacturing suites capable of handling increased batch sizes. A new customer experience center is also being constructed for clients who are visiting the site during development and/or manufacturing activities. Ground preparation and piling works are well under way, with an official groundbreaking ceremony taking place yesterday, February 7th.
Piramal Pharma Solutions is a global leader in ADC development and manufacturing, with hundreds of payloads developed and more than a thousand ADC batches manufactured. When complete, the expansion will enhance PPS' standing significantly by increasing ADC capacity at the Grangemouth site. The new facility will be fully supported by analytical laboratories (Quality Control, Cell-based Assay and Enzyme-Linked Immune Sorbent Assay [ELISA], Good Manufacturing Practice [GMP]), warehousing, and administrative offices, all housed in a purpose-built facility.
PPS's Grangemouth facility boasts two significant ADC capabilities: fit-for-purpose rapid development for early clinical materials and robust, scalable late phase development to support pivotal trials and commercial launch. By combining these skills with offerings from our other thirteen global facilities, including fill/finish, payloads, and peptides, we can provide integrated ADC services to customers looking for fast, simplified solutions.
Peter DeYoung, Chief Executive Officer, Piramal Pharma Solutions said, "We are delighted to announce the capacity expansion of our Grangemouth facility in the UK. This new development will more than double our ADC production capacity, strengthening our ability to service customers throughout the entire drug lifecycle. The primary driver behind this investment is the demand for commercial ADCs, coupled with a strong pipeline for clinical materials. This growth is a validation of Piramal Pharma Solutions' strong focus on Patient Centricity, its proven track record of service delivery, and the strategic initiatives and deep customer relationships."
This expansion represents an investment of 45 million pounds sterling, including a grant of £2.4 million from Scottish Enterprise, Scotland's national economic development agency.
Adrian Gillespie, Chief Executive of Scottish Enterprise, commented, "Piramal's investment is tremendous news for Scotland's life sciences sector, one of the largest life sciences clusters in Europe, and is creating new, high-quality jobs that are crucial to our economic recovery. With Scottish Enterprise support, the company's Grangemouth site expansion proposals will deliver more R&D and production capacity for the development, scale up and commercial manufacture of drugs in the global fight against cancer."
The Grangemouth expansion, which is also client co-funded, is designed to facilitate the continued evolution of the business through the commercialization of customer products, together with satisfying the strong pipeline of early phase clinical demand. The new facility is being built on a 5-acre brownfield plot less than 100 meters from the existing site and is designed to meet the highest standards of global compliance. It is expected that this expansion will create approximately 40-50 new jobs, bringing the total number of employees at the site to more than 250. The new hires will join a highly qualified scientific, technical, and professional staff that has already grown almost 4-fold in recent years.
Scottish Government Investment Minister Ivan McKeeadded, "This will be an important new development which could aid the treatment of life-threatening cancer, with Scottish Enterprise funding supporting the creation of 40 new jobs and safeguarding 170 more in Grangemouth."
"We are working with agencies like Scottish Enterprise to deliver support for manufacturing across Scotland. Investments like this are helping us build a strong industry which will boost our economic recovery and deliver future prosperity."
Morpeth Site API Investment
The investment in API capabilities at the Morpeth site, which is valued at approximately £10 million, includes new equipment, infrastructure, and utility systems. It is intended to meet increased market demand from global API customers while also improving PPS' carbon footprint by replacing obsolete equipment with new, energy-efficient alternatives. More than 400 people are employed at Morpeth, with ~160 directly in API Operations, and this investment helps safeguard their future while also improving the site's environmental impact. PPS is investing £8 million directly, while the UK government is contributing £2 million to the project.
Mr. DeYoung concluded, "PPS is firmly committed to keeping pace with the market through expansions and investments, but we are working hard to do so with a focus on sustainable and environmentally-responsible practices. As we enhance our capabilities at sites in North America and India, similar plans are in place."
About Piramal Pharma Solutions:
Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process & pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products & services, and potent solid oral drug product. Our track record as a trusted service provider with experience across varied technologies makes us a partner of choice for innovator and generic companies worldwide.
Piramal Pharma Limited (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network over 100 countries. PPL includes: Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business, and the India Consumer Healthcare business, selling over-the counter products. PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to innovator and generic companies. PCC's complex hospital product portfolio includes inhalation anaesthetics, intrathecal therapies for spasticity and pain management, injectable pain and anaesthetics, injectable anti-infectives, and other therapies. The Indian Consumer Healthcare business is among the leading players in India in the self-care space, with established brands in the Indian consumer healthcare market. In addition, PPL has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. In October 2020, the company received growth equity investment from the Carlyle Group.
Share this article